Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 62

Sort by

Sort Order Select

Journal Articles

CST6 Is a Small Autocrine Molecule That Targets Myeloma Growth and Bone Destruction

Dongzheng Gai, MD, Stewart JP, Xuxing Shen, Jin-Ran Chen, PhD, Can Li, MD, Bailu Peng, PhD, Ya-Wei Qiang, MD PhD, Shmuel Yaccoby, PhD, Maurizio Zangari, MD FACP, Frits van Rhee, MD, Guido J. Tricot, MD PhD, Lijuan Chen, MDPhD, John Shaughnessy, Jr., PhD, Fenghuang Zhan, MD PhD

Blood (2020) 136 (Supplement 1): 21.

https://doi.org/10.1182/blood-2020-140568

Published: 2020

Journal Articles

Iron Trafficking through Macrophages Regulates Signaling Pathways in Myeloma

Xuelian Tan, Timothy Cody Ashby, PhD, Yuqi Zhu, Can Li, MD, Xuxing Shen, MBBS, Qierra Brockman, BA, Dongzheng Gai, MD, Sarah K Johnson, PhD, Donghoon Yong, Carolina D. Schinke, MD, Maurizio Zangari, MD FACP, Frits van Rhee, MD, John Shaughnessy, Jr., PhD, Dingming Huang, PhD, Ivana Frech, DSc, PhD MBA, Guido J. Tricot, MD PhD, Fenghuang Zhan, MD PhD

Blood (2020) 136 (Supplement 1): 2.

https://doi.org/10.1182/blood-2020-140372

Published: 2020

Journal Articles

Long-Term Outcome of Total Therapy Regimens: Impact of Molecular Subgroups

Frits van Rhee, MD PhD, Maurizio Zangari, MD, Carolina D. Schinke, MD, Guido J. Tricot, MD PhD, Doug Steward, Susan Panozzo, Jeffery R. Sawyer, Brian A Walker, PhD, Joshua Epstein, DSc, Faith E. Davies, MD, Gareth Morgan, MD PhD, Adam Rosenthal, MS, Antje Hoering, PhD, Katherine K Nishimura, Bart Barlogie, MD PhD

Blood (2019) 134 (Supplement_1): 3309.

https://doi.org/10.1182/blood-2019-131870

Published: 2019

Journal Articles

Targeting NEK2 Induces Cellular Senescence in B-Cell Malignancies through p53-Independent Signaling Pathways

Yuqi Zhu, Ye Yang, PhD, Yogesh Jethava, MBBS,MDFRCPath,MRCP, Ivana Frech, DSc, PhD MBA, Guido J. Tricot, MD PhD, Fenghuang Zhan, MD PhD

Blood (2019) 134 (Supplement_1): 3102.

https://doi.org/10.1182/blood-2019-123815

Published: 2019

Journal Articles

TRIP13 Modulates Protein Deubiquitination to Promote Myeloma Progression

Can Li, MD, Reinaldo Franqui-Machin, Jiliang Xia, PhD, Gregory S. Thomas, Yogesh Jethava, MBBS,MDFRCPath,MRCP, Fangping Chen, MD PhD, Ivana Frech, DSc, PhD MBA, Guido J. Tricot, MD PhD, Fenghuang Zhan, MD PhD

Blood (2019) 134 (Supplement_1): 854.

https://doi.org/10.1182/blood-2019-123818

Published: 2019

Journal Articles

The Nek2 Genetic Knockout Mouse Model Provides Novel Treatment Strategies in Myeloma and Lymphoma

Li Can, MD, Kalyan Nadiminti, Yuqi Zhu, Yogesh Jethava, MBBS, MD FRCPath, MRCP, Ivana Frech, DSc, PhD MBA, Guido J. Tricot, MD PhD, Fenghuang Zhan, MD PhD

Blood (2018) 132 (Supplement 1): 5612.

https://doi.org/10.1182/blood-2018-99-115099

Published: 2018

Journal Articles

Early Intensive Therapy in Multiple Myeloma Using Tandem Transplantation with Novel Conditioning and Two Years Maintenance: A Single Institution Experience

Kalyan Nadiminti, MD, Christopher Strouse, MD, Praveen Vikas, MD, Lindsay Dozeman, Allyson Schultz, Sarah L Mott, Jillna Claus, Umar Farooq, MD, Margarida Silverman, MD, Michael Tomasson, MD, Fenghuang Zhan, MD PhD, Yogesh Jethava, MBBS, MDFRCPath, MRCP, Guido J. Tricot, MD PhD

Blood (2018) 132 (Supplement 1): 2152.

https://doi.org/10.1182/blood-2018-99-113890

Published: 2018

Journal Articles

Hematopoietic Cell Transplant-Comorbidity Index (HCT-CI) Score Predicts Non-Relapse Mortality (NRM) and Overall Survival (OS) in Multiple Myeloma Patients Undergoing Intensive Preparative Regimen with Autologous Stem Cell Transplantation (ASCT) Followed By Maintenance Therapy Using Novel Agents

Kalyan Nadiminti, MD, Umar Farooq, MD, Lindsay Dozeman, Sarah Mott, MS, Guido J. Tricot, MD PhD, Yogesh Jethava, MBBS,MDFRCPath,MRCP, Margarida Silverman, MD

Blood (2017) 130 (Supplement 1): 3281.

https://doi.org/10.1182/blood.V130.Suppl_1.3281.3281

Published: 2017

Journal Articles

Frequency and Outcome of Clinically Signficant Incidental Findings in Plasma Cell Dyscrasias Patients Undergoing Whole Body FDG PET-CT Scan

Ehsan Shabbir, MD, Sarah L Mott, Lindsay Dozeman, Umar Farooq, MD, Yogesh Jethava, MBBS,MDFRCPath,MRCP, Guido J. Tricot, MD PhD

Blood (2017) 130 (Supplement 1): 5376.

https://doi.org/10.1182/blood.V130.Suppl_1.5376.5376

Published: 2017

Journal Articles

The Interaction of NEK2 with USP7 Causes Resistance to Proteasome Inhibitor in Multiple Myeloma

Reinaldo Franqui-Machin, Mu Hao, PhD, Bai Hua, Zhimin Gu, PhD, Xin Zhan, Hongwei Xu, Hasem Habelhah, Yogesh Jethava, MBBS,MDFRCPath,MRCP, Lugui Qiu, MD, Ivana Frech, DSc, PhD MBA, Guido J. Tricot, MD PhD, Fenghuang Zhan, MD PhD

Blood (2017) 130 (Supplement 1): 593.

https://doi.org/10.1182/blood.V130.Suppl_1.593.593

Published: 2017

Journal Articles

C-Reactive Protein Monitoring Can Predict Neutropenic Fever during Autologous Hematopoietic Stem Cell Transplantation for Mutliple Myeloma

Vidya Kollu, MD, Sarah L Mott, Lindsay Dozeman, Fnu Rafiullah, MD, Umar Farooq, MD, Yogesh Jethava, MBBS,MDFRCPath,MRCP, Guido J. Tricot, MD PhD

Blood (2017) 130 (Supplement 1): 5529.

https://doi.org/10.1182/blood.V130.Suppl_1.5529.5529

Published: 2017

Journal Articles

Effect of Dosing Bortezomib According to Adjusted Body Surface Area in Multiple Myeloma

Susan Fajardo, PharmD, Marie Sirek, PharmD, Yogesh Jethava, MBBS,MDFRCPath,MRCP, Guido J. Tricot, MD PhD

Blood (2017) 130 (Supplement 1): 5406.

https://doi.org/10.1182/blood.V130.Suppl_1.5406.5406

Published: 2017

Journal Articles

Does Your Smoldering Myeloma Patient Need Treatment? Evidence Based Recommendations

Rafiullah, MD, Umar Zahid, MD, Irbaz Bin Riaz, MDMMSc, Ali McBride, PharmD,MS, Ahmad Iftikhar, MD, Yogesh Jethava, MBBS,MDFRCPath,MRCP, Guido J. Tricot, MD PhD, Faiz Anwer, MD

Blood (2017) 130 (Supplement 1): 5431.

https://doi.org/10.1182/blood.V130.Suppl_1.5431.5431

Published: 2017

Journal Articles

Multiple Myeloma Tumor Cells Are Selectively Killed By Pharmacologically-Dosed Ascorbic Acid

Reinaldo Franqui-Machin, Hongwei Xu, Yogesh Yethava, Ivana Frech, DSc, PhD MBA, Guido J. Tricot, MD PhD, Fenghuang Zhan, MD PhD

Blood (2017) 130 (Supplement 1): 5391.

https://doi.org/10.1182/blood.V130.Suppl_1.5391.5391

Published: 2017

Journal Articles

A Single Autologous Stem Cell Transplant (ASCT) Followed By Two Years of Post-Transplant Therapy Is Safe in Older Recently Diagnosed Multiple Myeloma (MM) Patients. Preliminary Results from the Prospective Phase II Trial (NCT01849783)

Kalyan Nadiminti, MD, Lindsay Dozeman, Annick Tricot, Allyson Schultz, Sheila Ouverson, Fenghuang Zhan, MD PhD, Margarida Silverman, MD, Guido J. Tricot, MD PhD, Yogesh Jethava, MBBS,MDFRCPath,MRCP

Blood (2017) 130 (Supplement 1): 4543.

https://doi.org/10.1182/blood.V130.Suppl_1.4543.4543

Published: 2017

Journal Articles

Clinical Investigation of Mitochondrial Biogenesis in Multiple Myeloma

Xin Zhan, Reinaldo Franqui-Machin, Kalyan Nadiminti, MD, Huojun Cao, Brad A. Amendt, Yogesh Jethava, MBBS,MDFRCPath,MRCP, Ivana Frech, DSc, PhD MBA, Fenghuang Zhan, MD PhD, Guido J. Tricot, MD PhD

Blood (2017) 130 (Supplement 1): 1785.

https://doi.org/10.1182/blood.V130.Suppl_1.1785.1785

Published: 2017

Journal Articles

Nek2 Stabilization By Usp7 Leads to Activation of NF-Kb in Multiple Myeloma

Reinaldo Franqui Machin, BS, Xin Zhan, BA, Hongwei Xu, DDS, Ivana Frech, DSc, PhD MBA, Guido J Tricot, MD PhD, Fenghuang Zhan, MD PhD

Blood (2016) 128 (22): 4418.

https://doi.org/10.1182/blood.V128.22.4418.4418

Published: 2016

Journal Articles

Drug Resistant Myeloma Cells Cause More Severe Bone Destruction in Myeloma

Mu Hao, MD PhD, Zhimin Gu, PhD, Reinaldo Franqui Machin, Hongwei Xu, Gregory S. Thomas, PhD, Lugui Qiu, MD PhD, Guido J Tricot, MD PhD, Fenghuang Zhan, MD PhD

Blood (2015) 126 (23): 839.

https://doi.org/10.1182/blood.V126.23.839.839

Published: 2015

Journal Articles

Bortezomib, Dexamethasone, Thalidomide and Melphalan (VDT-Mel) Preparative Regimen in Autologous Stem Cell Transplant (ASCT) Results in a Very High Stringent CR (sCR) Rate in Multiple Myeloma (MM)

Kalyan Nadiminti, MD, Kamal Kant Singh Abbi, MBBS, Annick Tricot, Allyson Schultz, Lindsay Dozeman, Sarah L Mott, MS, Fenghuang Zhan, MD PhD, Guido J Tricot, MD PhD

Blood (2015) 126 (23): 1971.

https://doi.org/10.1182/blood.V126.23.1971.1971

Published: 2015

Journal Articles

Elevated Rates of Monoclonal Gammopathy in High-Risk Chronic Lymphocytic Leukemia Pedigrees

Nicola J Camp, PhD, Rosalie G Waller, BS, Cassandra Garner, BS, Guido J Tricot, MD PhD, Michael Tomasson, MD, Djordje Atanackovic, MD, Martha Glenn, MD

Blood (2015) 126 (23): 1449.

https://doi.org/10.1182/blood.V126.23.1449.1449

Published: 2015

NARROW

CST6 Is a Small Autocrine Molecule That Targets Myeloma Growth and Bone Destruction

Iron Trafficking through Macrophages Regulates Signaling Pathways in Myeloma

Long-Term Outcome of Total Therapy Regimens: Impact of Molecular Subgroups

Targeting NEK2 Induces Cellular Senescence in B-Cell Malignancies through p53-Independent Signaling Pathways

TRIP13 Modulates Protein Deubiquitination to Promote Myeloma Progression

The Nek2 Genetic Knockout Mouse Model Provides Novel Treatment Strategies in Myeloma and Lymphoma

Early Intensive Therapy in Multiple Myeloma Using Tandem Transplantation with Novel Conditioning and Two Years Maintenance: A Single Institution Experience

Hematopoietic Cell Transplant-Comorbidity Index (HCT-CI) Score Predicts Non-Relapse Mortality (NRM) and Overall Survival (OS) in Multiple Myeloma Patients Undergoing Intensive Preparative Regimen with Autologous Stem Cell Transplantation (ASCT) Followed By Maintenance Therapy Using Novel Agents

Frequency and Outcome of Clinically Signficant Incidental Findings in Plasma Cell Dyscrasias Patients Undergoing Whole Body FDG PET-CT Scan

The Interaction of NEK2 with USP7 Causes Resistance to Proteasome Inhibitor in Multiple Myeloma

C-Reactive Protein Monitoring Can Predict Neutropenic Fever during Autologous Hematopoietic Stem Cell Transplantation for Mutliple Myeloma

Effect of Dosing Bortezomib According to Adjusted Body Surface Area in Multiple Myeloma

Does Your Smoldering Myeloma Patient Need Treatment? Evidence Based Recommendations

Multiple Myeloma Tumor Cells Are Selectively Killed By Pharmacologically-Dosed Ascorbic Acid

A Single Autologous Stem Cell Transplant (ASCT) Followed By Two Years of Post-Transplant Therapy Is Safe in Older Recently Diagnosed Multiple Myeloma (MM) Patients. Preliminary Results from the Prospective Phase II Trial (NCT01849783)

Clinical Investigation of Mitochondrial Biogenesis in Multiple Myeloma

Nek2 Stabilization By Usp7 Leads to Activation of NF-Kb in Multiple Myeloma

Drug Resistant Myeloma Cells Cause More Severe Bone Destruction in Myeloma

Bortezomib, Dexamethasone, Thalidomide and Melphalan (VDT-Mel) Preparative Regimen in Autologous Stem Cell Transplant (ASCT) Results in a Very High Stringent CR (sCR) Rate in Multiple Myeloma (MM)

Elevated Rates of Monoclonal Gammopathy in High-Risk Chronic Lymphocytic Leukemia Pedigrees

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only